Literature DB >> 15251133

Inhibition of IL-6 for the treatment of inflammatory diseases.

Norihiro Nishimoto1, Tadamitsu Kishimoto.   

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine with various biological activities. Deregulated overproduction of IL-6 has been found to play pathological roles in chronic inflammatory diseases such as rheumatoid arthritis, Castleman's disease, juvenile idiopathic arthritis and Crohn's disease. Humanized anti-IL-6 receptor antibody has been developed as a therapeutic agent for these diseases, and therapeutic benefits have been revealed in clinical studies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15251133     DOI： 10.1016/j.coph.2004.03.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  47 in total

1.  IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Chikahisa Higuchi; Makoto Hirao; Michio Okamoto; Kota Koizumi; Tokimitsu Morimoto; Hideki Yoshikawa; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

2.  Cell encapsulating biomaterial regulates mesenchymal stromal/stem cell differentiation and macrophage immunophenotype.

Authors:  David Antonio Cantu; Peiman Hematti; Weiyuan John Kao
Journal:  Stem Cells Transl Med       Date:  2012-10-10       Impact factor: 6.940

3.  Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.

Authors:  Bailin Liang; Debra B Gardner; Don E Griswold; Peter J Bugelski; Xiao Yu R Song
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

Review 4.  New therapies for rheumatoid arthritis.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

5.  Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation.

Authors:  David A Braun; Miguel Fribourg; Stuart C Sealfon
Journal:  J Biol Chem       Date:  2012-11-19       Impact factor: 5.157

6.  Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.

Authors:  Weirong Wang; Xiaofeng Wang; Rajitha Doddareddy; Damien Fink; Thomas McIntosh; Hugh M Davis; Honghui Zhou
Journal:  AAPS J       Date:  2013-11-28       Impact factor: 4.009

7.  Enhancement of anti-inflammatory tendency by SB203580, p38alpha specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A.

Authors:  Seon Kyu Han; Su Jin Jeon; Keiji Miyazawa; Seh Yoon Yi; Young Sook Yoo
Journal:  Rheumatol Int       Date:  2006-03-11       Impact factor: 2.631

8.  Early administration of IL-6RA does not prevent radiation-induced lung injury in mice.

Authors:  Toshiyuki Ogata; Hideya Yamazaki; Teruki Teshima; Ayaka Kihara; Yuko Suzumoto; Takehiro Inoue; Norihiro Nishimoto; Nariaki Matsuura
Journal:  Radiat Oncol       Date:  2010-04-07       Impact factor: 3.481

Review 9.  Mechanisms of growth impairment in pediatric Crohn's disease.

Authors:  Thomas D Walters; Anne M Griffiths
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

Review 10.  Biological targets for therapeutic interventions in COPD: clinical potential.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Caputi; Rosario Maselli; Serafino A Marsico
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.